Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 8/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6065132 | 1.00 | TSHR (0.52) | TSHRSMN1; SMN2CA2MAPK1ACHE | |
| SCHEMBL8948119 | 0.88 | TSHR (0.35) | TSHRSMN1; SMN2CA2MAPK1ACHE | |
| SCHEMBL8948114 | 0.88 | TSHR (0.35) | TSHRSMN1; SMN2CA2MAPK1ACHE | |
| SCHEMBL4826149 | 0.84 | ACHE (0.53) | TSHRSMN1; SMN2CA2MAPK1ACHE | |
| SCHEMBL4826151 | 0.84 | ACHE (0.53) | TSHRSMN1; SMN2CA2MAPK1ACHE | |
| SCHEMBL8580321 | 0.83 | KDM4E (0.32) | TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL8580318 | 0.83 | KDM4E (0.32) | TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL7652587 | 0.81 | TSHR (0.48) | TSHRSMN1; SMN2CA2MAPK1ACHE | |
| SCHEMBL7652590 | 0.81 | TSHR (0.48) | TSHRSMN1; SMN2CA2MAPK1ACHE | |
| SCHEMBL3720872 | 0.78 | ACHE (0.47) | TSHRSMN1; SMN2CA2MAPK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638913-A1 | PROCESSES FOR PREPARING BETA-HYDROXY-KETONES AND ALPHA, BETA-UNSATURATED KETONES | EASTMAN CHEMICAL COMPANY (US) | 2006-03-29 | — | — | EP | claimed |
| US-6960694-B2 | Processes for preparing β-hydroxy-ketones and α,β-unsaturated ketones | EASTMAN CHEMICAL COMPANY (US) | 2005-11-01 | — | — | US | claimed |
| WO-2005005361-A1 | PROCESSES FOR PREPARING BETA-HYDROXY-KETONES AND ALPHA, BETA-UNSATURATED KETONES | EASTMAN CHEMICAL COMPANY (US) | 2005-01-20 | — | — | WO | claimed |
| US-20050004401-A1 | Processes for preparing beta-hydroxy-ketones and alpha,beta-unsaturated ketones | EASTMAN CHEMICAL COMPANY | 2005-01-06 | — | — | US | claimed |
| US-5484949-A | Method for the synthesis of α β-unsaturated ketones | NIPPON SODA CO., LTD. (JP) | 1996-01-16 | — | — | US | disclosed |
| EP-0454867-A1 | A METHOD FOR THE SYNTHESIS OF -g(a), -g(b)-UNSATURATED KETONES. | NIPPON SODA CO (JP) | 1991-11-06 | — | — | EP | disclosed |
| WO-1991007370-A1 | A METHOD FOR THE SYNTHESIS OF α, β-UNSATURATED KETONES | NIPPON SODA CO., LTD. (JP) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004401-A1 | Processes for preparing beta-hydroxy-ketones and alpha,beta-unsaturated ketones | EBP, CYP8B1, BCKDK | TSHR 4352/4885SMN1; SMN2 2104/4885CA2 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.